BACE1 and Alzheimer disease: In this study, KLF5 was demonstrated to be a key transcriptional activator of BACE1, and the inhibition of the KLF5 expression could ameliorate cognitive deficits and Aβ pathology by reducing APP amyloid cleavage in the AD mouse model.